A
Agilent Technologies Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Market Cap: 38.2 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE, INC.
Website: https://www.agilent.com/
Shares Outstanding: 307 Million
Float: 0
Dividend: 0.732093164670622 (0.01%)
Beta: 0.905793440164726
Sector: Professional, Scientific, and Technical Services
Industry: Testing Laboratories
Ethical Flags
Longest drawdown: 874 trading days
From: 2014-01-22 To: 2017-07-12
Lowest Point:
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
via: Business Wire at 2019-06-11 03:56:00:000
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA (pembrolizumab) Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx assay for expand… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2021-01-04 | 2021-01-27 | 2021-01-05 | 2020-11-18 | 0.194000005722046 | Cash | |||
| 2020-10-05 | 2020-10-28 | 2020-10-06 | 2020-09-16 | 0.18 | Cash | |||
| 2020-06-29 | 2020-07-22 | 2020-06-30 | 2020-05-20 | 0.18 | Cash | |||
| 2020-03-30 | 2020-04-22 | 2020-03-31 | 2020-03-18 | 0.18 | Cash | |||
| 2019-12-30 | 2020-01-22 | 2019-12-31 | 2019-11-20 | 0.18 | Cash | |||
| 2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | Cash | |||
| 2019-09-30 | 2019-10-23 | 2019-10-01 | 2019-09-18 | 0.164 | No Change QoQ | |||
| 2019-07-01 | 2019-07-24 | 2019-07-02 | 2019-05-22 | 0.164 | No Change QoQ | |||
| 2019-04-01 | 2019-04-24 | 2019-04-02 | 2019-03-20 | 0.164 | No Change QoQ | |||
| 2018-12-28 | 2019-01-23 | 2018-12-31 | 2018-11-14 | 0.164 | Increase | |||
| 2018-10-01 | 2018-10-24 | 2018-10-02 | 2018-09-19 | 0.149 | No Change QoQ | |||
| 2018-07-02 | 2018-07-25 | 2018-07-03 | 2018-05-16 | 0.149 | No Change QoQ | |||
| 2018-04-02 | 2018-04-25 | 2018-04-03 | 2018-03-21 | 0.149 | No Change QoQ | |||
| 2017-12-29 | 2018-01-24 | 2018-01-02 | 2017-11-15 | 0.149 | Increase | |||
| 2017-10-02 | 2017-10-25 | 2017-10-03 | 2017-09-20 | 0.132 | No Change QoQ | |||
| 2017-06-29 | 2017-07-26 | 2017-07-03 | 2017-05-17 | 0.132 | No Change QoQ | |||
| 2017-03-31 | 2017-04-26 | 2017-04-04 | 2017-03-15 | 0.132 | No Change QoQ | |||
| 2016-12-29 | 2017-01-25 | 2017-01-03 | 2016-11-17 | 0.132 | Increase | |||
| 2016-09-30 | 2016-10-26 | 2016-10-04 | 2016-09-21 | 0.115 | No Change QoQ | |||
| 2016-06-30 | 2016-07-27 | 2016-07-05 | 2016-05-18 | 0.115 | No Change QoQ | |||
| 2016-04-01 | 2016-04-27 | 2016-04-05 | 2016-03-16 | 0.115 | No Change QoQ | |||
| 2015-12-31 | 2016-01-27 | 2016-01-05 | 2015-11-19 | 0.115 | Increase | |||
| 2015-09-25 | 2015-10-21 | 2015-09-29 | 2015-09-16 | 0.1 | No Change QoQ | |||
| 2015-06-26 | 2015-07-22 | 2015-06-30 | 2015-05-20 | 0.1 | No Change QoQ | |||
| 2015-03-27 | 2015-04-22 | 2015-03-31 | 2015-03-18 | 0.1 | No Change QoQ | |||
| 2015-01-02 | 2015-01-28 | 2015-01-06 | 2014-11-20 | 0.1 | Decrease | |||
| 2014-09-26 | 2014-10-22 | 2014-09-30 | 2014-09-17 | 0.132 | No Change QoQ |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|